Lynparza (olaparib)

References

  1. Lynparza (olaparib) Summary of Product Characteristics.
  2. Ray-Coquard, I. et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N. Engl. J. Med. 381, 2416–2428 (2019).
  3. Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer TA10526 l Guidelines and guidance l NICE.
  4. Lynparza (olaparib) 50 mg hard capsules Summary of Product Characteristics. 
  5. Moore, K. et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 379, 2495–2505 (2018).
  6. Eng, K. H., Hanlon, B. M., Bradley, W. H. & Szender, J. B. Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. Gynecol. Oncol. 139, 228–235 (2015).
  7. Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I. & D’Andrea, A. D. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 5, 1137–1154 (2015).
  8. myChoice® HRD Ovarian Cancer. Myriad MyChoice https://myriadmychoice.com/portfolio/ovarian-cancer/mychoice-hrd-ovarian-cancer/. Accessed April 2021.
  9. Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1. Abstract #811MO. (19-21 September).
  10. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy TA598 l Guidence and guidelines l NICE.
  11. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer TA620 l Guidance and guidelines l NICE.
  12. Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund l NICE. https://www.nice.org.uk/news/article/ovarian-cancer-patients-to-have-nice-approved-drug-combination-option-on-cancer-drugs-fund. Accessed April 2021.
  13. Scottish Medicines Consortium. Olaparib 100mg and 150mg film-coated tablets (Lynparza). SMC No. (2209). https://www.scottishmedicines.org.uk/media/4940/olaparib-lynparza-final-november-2019- for-website.pdf. Accessed April 2021.
  14. Scottish Medicines Consortium. Re-submission - olaparib, 50mg, hard capsules (Lynparza). SMC No. (1047/15). https://www.scottishmedicines.org.uk/files/advice/olaparib_Lynparza_Resub_FINAL_Oct_2016_revised_201016_for_website.pdf. Accessed April 2021.
  15. Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861 (2014).
  16. Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017).
  17. Ledermann, J. et al. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. N. Engl. J. Med. 366, 1382–1392 (2012).
  18. Friedlander, M. et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br. J. Cancer 119, 1075–1085 (2018).
  19. Poveda, A et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: a Phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Abstract #6002. Supplementary materials. (29-31 May).
  20. Friedlander, M. & Matulonis, U. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy (Supplementary appenix). Br. J. Cancer 119, Appendix (2018).
  21. Avastin (bevacizumab) Summary of Product Characteristics.

GB-22967 April 2021

Back to top